ArticleFrontiers in oncology2026

Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China.

Zhangyuting He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.